Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Ozone Friendly Formulation, Flovent HFA (Fluticasone Propionate HFA) Inhalation Aerosol, Now Available in US RESEARCH TRIANGLE PARK, NC -- February 7, 2005 -- GlaxoSmithKline announced today that Flovent® HFA (fluticasone propionate HFA) Inhalation Aerosol, a reformulated version of the asthma medication Flovent® (fluticasone propionate) Inhalation Aerosol, will become available in pharmacies on March 1. Flovent HFA will replace Flovent Inhalation Aerosol, which used chlorofluorocarbon (CFC) to propel the medication out of the canister and into the lungs. The new formulation uses a more ozone friendly propellant, hydrofluoroalkane (HFA-134a). With the introduction of Flovent HFA and the phase-out of the CFC- containing Flovent product, GlaxoSmithKline will successfully complete the transition of its respiratory products to CFC-free formulations. "We are very proud to be the first company in the U.S. to achieve the transition of our asthma and COPD medicines to CFC-free formulations," said Stan Hull, senior vice-president, GlaxoSmithKline. "This has been a significant undertaking, involving substantial work and resources, but we're pleased to achieve our goal of a 100% CFC-free portfolio without disrupting patient access to these very important medicines." Flovent HFA Flovent is an inhaled corticosteroid that helps to reduce inflammation in the airways -- one of the main components of asthma. Flovent HFA was approved by the Food & Drug Administration in May 2004 and is indicated for the maintenance treatment of asthma as a preventative therapy in patients 12 years of age and older. Flovent is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirements for oral corticosteroids over time. Adrenal insufficiency may occur when transferring patients from systemic steroids to inhaled steroids. Flovent does not replace fast-acting inhalers for sudden symptoms. In clinical trials of adults and adolescents, Flovent HFA demonstrated comparable safety and efficacy to the CFC Flovent product. For both formulations, most adverse events were mild to moderate in severity, and the most common side effects were upper respiratory tract infection, headache, throat irritation, and sinusitis. With the introduction of Flovent HFA, the CFC formulation of Flovent will be phased out of distribution by mid-March 2005. SOURCE: GlaxoSmithKline E-mail this page to a friend or colleague! To print, use this version